JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Decker, M. W.
Right arrow Articles by Arneric, S. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Decker, M. W.
Right arrow Articles by Arneric, S. P.

Vol. 283, Issue 1, 247-258, 1997

ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A Novel Cholinergic Channel Modulator with Effects on Cognitive Performance in Rats and Monkeys

Michael W. Decker, Anthony W. Bannon, Peter Curzon, Karen L. Gunther, Jorge D. Brioni, Mark W. Holladay, Nan-Horng Lin, Yihong Li, Jerome F. Daanen, Jerry J. Buccafusco , Mark A. Prendergast, William J. Jackson and Stephen P. Arneric

Neurological and Urological Diseases Research, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois (M.W.D., A.W.B., P.C., K.L.G., J.D.B., M.W.H., N.-H.L., Y.L., J.F.D., S.P.A.), Department of Pharmacology and Toxicology (J.J.B., M.A.P.) and Department of Physiology and Endocrinology (W.J.J.), Medical College of Georgia and Medical Research Service (J.J.B.,W.J.J.), Veterans Administration Medical Center, Augusta, Georgia

ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride], a novel ligand at neuronal nicotinic acetylcholine receptors with reduced adverse effects and improved oral bioavailability relative to (-)-nicotine, was tested in a variety of cognitive tests in rats and monkeys. Administered acutely, ABT-089 only marginally improved the spatial discrimination water maze performance of septal-lesioned rats. However, more robust improvement (45% error reduction on the last training day) was observed when ABT-089 was administered continuously via subcutaneous osmotic pumps (minimum effective dose: 1.3 µmol/kg/day). Continuous infusion of (-)-nicotine produced comparable improvement in the spatial discrimination water maze performance of septal-lesioned rats, but a 40-fold higher dose of (-)-nicotine was required (62 µmol/kg/day). Continuous infusion of ABT-089 to aged rats enhanced spatial learning in a standard Morris water maze, as indexed by spatial bias exhibited during a probe trial conducted after 4 days of training, but not when they were subsequently trained in a two-platform spatial discrimination water maze. The compound induced a small impairment in young rats on the standard water maze, but not on the two-platform task. A probe trial conducted after additional training in the standard water maze revealed no age or drug effects. ABT-089 did not affect performance of either the aged or young rats during inhibitory (passive) avoidance training. Also, continuous infusion of ABT-089 did not affect responses to acoustic startle or prepulse inhibition of acoustic startle in young, aged or septal-lesioned rats and did not affect locomotor activity in either sham-lesioned or septal-lesioned rats. In monkeys, acute administration of ABT-089 modestly improved the delayed matching-to-sample performance of mature, adult monkeys and more robustly improved performance in aged monkeys. Improved performance in the aged monkeys was restricted to the longest delay intervals and was not accompanied by changes in response latencies.


Copyright © by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Neurosci.Home page
V. Parikh, K. Man, M. W. Decker, and M. Sarter
Glutamatergic Contributions to Nicotinic Acetylcholine Receptor Agonist-Evoked Cholinergic Transients in the Prefrontal Cortex
J. Neurosci., April 2, 2008; 28(14): 3769 - 3780.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
R. U. Ostrovskaya, M. A. Gruden, N. A. Bobkova, R. D. E. Sewell, T. A. Gudasheva, A. N. Samokhin, S. B. Seredinin, W. Noppe, V. V. Sherstnev, and L. A. Morozova-Roche
The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model
J Psychopharmacol, August 1, 2007; 21(6): 611 - 619.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
G. B. Fox, T. A. Esbenshade, J. B. Pan, R. J. Radek, K. M. Krueger, B. B. Yao, K. E. Browman, M. J. Buckley, M. E. Ballard, V. A. Komater, et al.
Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist
J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 176 - 190.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
B. Bontempi, K. T. Whelan, V. B. Risbrough, T. S. Rao, J. J. Buccafusco, G. K. Lloyd, and F. Menzaghi
SIB-1553A, ({+/-})-4-{[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio}phenol Hydrochloride, a Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors with Putative Cognitive-Enhancing Properties: Effects on Working and Reference Memory Performances in Aged Rodents and Nonhuman Primates
J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 297 - 306.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. J. Buccafusco and A. V. Terry Jr.
Multiple Central Nervous System Targets for Eliciting Beneficial Effects on Memory and Cognition
J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 438 - 446.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
J. P. Sullivan, D. Donnelly-Roberts, C. A. Briggs, D. J. Anderson, M. Gopalakrishnan, I. C. Xue, M. Piattoni-Kaplan, E. Molinari, J. E. Campbell, D. G. Mckenna, et al.
ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A Potent and Selective Cholinergic Channel Modulator with Neuroprotective Properties
J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 235 - 246.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.